Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 4 (2007), Issue 2 (February)

1. The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome.
   Curr Opin Rheumatol, 19(2): 197-203. [Abstract] [Full-text]
2. Cardiovascular risk factors, fitness and physical activity in rheumatic diseases.
   Curr Opin Rheumatol, 19(2): 190-6. [Abstract] [Full-text]
3. Outcomes in rheumatoid arthritis: incorporating the patient perspective.
   Curr Opin Rheumatol, 19(2): 101-5. [Abstract] [Full-text]
4. Health literacy and arthritis research and practice.
   Curr Opin Rheumatol, 19(2): 97-100. [Abstract] [Full-text]
5. Work disability in rheumatic diseases.
   Curr Opin Rheumatol, 19(2): 91-6. [Abstract] [Full-text]
6. Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.
   Exp Eye Res, 84(3): 500-12. [Abstract] [Full-text]
7. Daily fatigue in women with osteoarthritis, rheumatoid arthritis, and fibromyalgia.
   Pain, 128(1): 128-35. [Abstract] [Full-text]
8. Functional staging and surgical intervention of the elbow and shoulder joints in a patient with rheumatoid arthritis.
   Nat Clin Pract Rheumatol, 3(2): 112-7; quiz 1 p following 117. [Abstract] [Full-text]
9. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver.
   Eur J Pharmacol, 558(1): 199-207. [Abstract] [Full-text]
10. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis.
    Stat Med, 26(6): 1237-54. [Abstract] [Full-text]
11. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.
    Arthritis Rheum, 57(1): 125-32. [Abstract] [Full-text]
12. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection.
    Arthritis Rheum, 57(1): 161-70. [Abstract] [Full-text]
13. Economic impact of juvenile idiopathic arthritis.
    Arthritis Rheum, 57(1): 44-8. [Abstract] [Full-text]
14. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
    Arthritis Rheum, 57(1): 133-9. [Abstract] [Full-text]
15. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression.
    Arthritis Rheum, 57(1): 116-24. [Abstract] [Full-text]
16. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study.
    Arthritis Rheum, 57(1): 35-43. [Abstract] [Full-text]
17. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study.
    Arthritis Rheum, 56(2): 647-57. [Abstract] [Full-text]
18. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis.
    Arthritis Rheum, 56(2): 639-46. [Abstract] [Full-text]
19. Amelioration of collagen-induced arthritis in rats by nanogold.
    Arthritis Rheum, 56(2): 544-54. [Abstract] [Full-text]
20. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells.
    Arthritis Rheum, 56(2): 531-43. [Abstract] [Full-text]
21. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis.
    Arthritis Rheum, 56(2): 521-30. [Abstract] [Full-text]
22. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis.
    Arthritis Rheum, 56(2): 509-20. [Abstract] [Full-text]
23. Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent.
    Arthritis Rheum, 56(2): 498-508. [Abstract] [Full-text]
24. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes.
    Arthritis Rheum, 56(2): 464-75. [Abstract] [Full-text]
25. Vaccination with selected synovial T cells in rheumatoid arthritis.
    Arthritis Rheum, 56(2): 453-63. [Abstract] [Full-text]
26. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Arthritis Rheum, 56(2): 448-52. [Abstract] [Full-text]
27. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis.
    Arthritis Rheum, 56(2): 441-7. [Abstract] [Full-text]
28. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
    Arthritis Rheum, 56(2): 425-32. [Abstract] [Full-text]
29. Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis.
    Biochem Biophys Res Commun, 355(2): 392-7. [Abstract] [Full-text]
30. Radiation synovectomy using 188Re-tin colloid improves knee synovitis as shown by MRI in refractory rheumatoid arthritis.
    Nucl Med Commun, 28(4): 239-44. [Abstract] [Full-text]

© 2004-2008 Rheumatoid Arthritis Research Today. All Rights Reserved.